Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Zymo's Methyl-Seq and 5-hmC Prep Kits; Gene Codes' Sequencher 5.2


Zymo Research Corporation has launched Pico Methyl-Seq Library Prep and RRHP 5-hmC Library Prep kits for next-gen sequencing-based analysis of 5-methylcytosine and 5-hydroxymethylcytosine, respectively. The kits are compatible with next-gen sequencing on Illumina platforms. The Pico Methyl-Seq kit is a modified whole-genome bisulfite sequencing library prep workflow that can be completed in less than six hours, according to the company. The RRHP 5-hmC kit uses a reduced representation hydroxymethylation profiling protocol that requires 100 ng of input DNA, is quantitative and strand-specific.

Gene Codes Corporation has released Sequencher 5.2, the latest release of its DNA sequencing software that can analyze both Sanger sequencing data and next-gen sequencing data. A new addition to the software is Sequencher Connections, which integrates Sequencher with third-party tools.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.